BSEAGM/EGM4d ago · 30 Jul 2026, 05:00 pm

Notice of 33rd Annual General Meeting for the Financial Year 2025-26.

Oxygenta Pharmaceutical Ltd · 524636

✦ AI SummaryResults

Oxygenta Pharmaceutical Ltd submitted a notice of its 33rd Annual General Meeting for the financial year 2025-26, scheduled to be held on August 21, 2026, through video conferencing. The meeting will consider and adopt the audited financial statements for the year ended March 31, 2026, and appoint a director in place of Mr. Balasubba Reddy Mamilla, who retires by rotation.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Oxygenta Pharmaceutical Ltd - 524636 - Submission Of Notice Of 33Rd Annual General Meeting For The Finanical Year 2025-26.

Attachments (1)

📄

2a269c95-e426-46f0-908d-01776bcf7752.pdf

pdf

Download →
View document text
VIRUPAKSHA To Date: 30.07.2026 The Manager BSE Limited P.J. Towers, Dalal Street Mumbai-400001 Dear Sit/ Madam, Sub: Submission of Notice of 33" Annual General Meeting for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR) Regulations, 2015. Unit: Oxygenta Pharmaceutical Limited In Compliance with Regulation 34 of SEBI (LODR) Regulations, 2015, we are herewith submitting the Notice of the 33 Annual General Meeting for the Financial Year 2025-26. The Annual General Meeting of the Company is scheduled to be held on Friday, 21* August, 2026 at 10:30 A.M. through Video Conference “VC” / Other Audio-Visual Means. The annual report along with the notice was dispatched on 30™ July, 2026. Further, pursuant to Regulation 36(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a letter providing the web-link of the Annual Report, being sent to those members who have not registered their e-mail address, is available on the Company’s website at https:/www.oxygentapharma.com/ . This is for the information and records of the exchange, please. Thanking You. Yours faithfully, For Oxygenta Pharmaceutical Limited Balasubba Reddy Mamilla Executive Director (DIN: 01998852) OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An 1SO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company) Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad — 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com, Phone 040-23073417, CIN: L24110TG1990PLC012038 OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26 OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26 CORPORATE INFORMATION BOARD OF DIRECTORS: Mr. Balasubba Reddy Mamilla - Whole Time Director (DIN:01998852) Mr. Chandra Mouliswar Reddy Gangavaram - Whole Time Director (DIN:00046845) Mr. Sidda Reddy Kanuparthi - Independent Director (DIN:07156289) Mrs. Vedavathi Gangavaram - Non-Executive Director (DIN:02870966) Dr. Veera Reddy Arava - Independent Director (DIN:10832178) Mrs. Sharvari Swapnil Shinde - Independent Director (DIN:11149764) *Mr. Amireddy Venkatesu Reddy - Additional Director (Executive Category) (DIN:11087687) *Mr. Janardhana Reddy Yeddula - Additional Director (Independent Category) (DIN:03207357) *#Chief Financial Officer - Mr. Prasad Reddy Battinapatla ^Company Secretary and Compliance Officer - Ms. Kumkum Bajaj *Appointed w.e.f. 23rd May, 2026. *#Appointed w.e.f. 07th November, 2025. ^ Appointed w.e.f. 14th August, 2025. Corporate Identity Number (CIN) - L24110TG1990PLC012038 ISIN - INE102E01018 REGISTERED OFFICE: Survey No.252/1, Aroor Village, Sadasivapet Mandal, Medak District, Medak, Telangana, India – 502291 CORPORATE OFFICE: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township, Hyderabad, Rangareddy, Telangana, India, 500037 STATUTORY AUDITORS M/s. A.M. Reddy & D.R. Reddy, Chartered Accountants H. No. 3-6-640/1/C, 4th floor, Street no.9 Himayat Nagar, Hyderabad, Telangana, India -500029. (Firm Registration No. 0090685) SECRETARIAL AUDITORS M/s. Aakanksha Dubey & Co Practicing Company Secretaries, H. No. 11-1-439/301, 3rd Floor, Baba Residency, Sitaphalmandi, Secunderabad – 500061 (Firm Registration Number: S2025TS1021000) INTERNAL AUDITORS M/s. Suryachandra & Associates, Chartered Accountants Plot No 10, House no 8-3-315/8, Beside MGM International School, Maruthi Nagar, Yousufguda, Hyderabad- 500045 (Firm Registration No.004297S) OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26 COST AUDITORS M/s. PCR & Associates, Cost Accountants, Plot No. 80/A, Flat No 402, 4th Floor, Srinivasam Apartment, Western Hills, Pragati Nagar Road, Opp. JNTU, Kukatpally, Hyderabad, Telangana, India- 500085 (Firm Registration No. 000355) BANKERS Kotak Mahendra Bank Limited CONSTITUTION OF COMMITTEES: AUDIT COMMITTEE: Mr. Sidda Reddy Kanuparthi - Chairman Mrs. Sharvari Swapnil Shinde - Member Dr. Veera Reddy Arava - Member Mr. Chandra Mouliswar Reddy Gangavaram - Member NOMINATION AND REMUNEARTION COMMITTEE: Dr. Veera Reddy Arava - Chairman Mr. Sidda Reddy Kanuparthi - Member Mrs. Sharvari Swapnil Shinde - Member STAKEHOLDER RELATIONSHIP COMMITTEE: Dr. Veera Reddy Arava - Chairman Mr. Sidda Reddy Kanuparthi - Member Mrs. Sharvari Swapnil Shinde - Member Mr. Balasubba Reddy Mamilla - Member LISTED AT: BSE Limited REGISTRAR & SHARE TRANSFER AGENTS: M/s. Venture Capital & Corporate Investments Private Ltd AURUM, Door No.4-50/P-II/57/4F & 5F, Plot No.57, 4th & 5th Floors, Jayabheri Enclave Phase– II, Gachibowli, Hyderabad – 500032 Contact No: +91 040 23818475 / +91 040 35164940 E-mail: investor.relations@vccipl.com Website: https://www.vccipl.com/ CONTACT DETAILS: Cell : 040-23073417 E-Mail : cs@oxygentapharma.com Website: https://www.oxygentapharma.com/index.html OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26 NOTICE Notice is hereby given that the 33rd Annual General Meeting of the members of Oxygenta Pharmaceutical Limited will be held on Friday, 21st day of August, 2026 at 10:30 A.M. through Video Conferencing/ Other Audio Visual Means (OAVM), to transact the following business: ORDINARY BUSINESS: 1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31st March 2026, together with the Reports of the Board of Directors and Auditor’s thereon. 2. To appoint a director in place of Mr. Balasubba Reddy Mamilla (DIN: 01998852), who retires by rotation and being eligible, offers himself for re-appointment. “RESOLVED THAT pursuant to the applicable provisions of Section 152 and other applicable provisions of the Companies Act, 2013, Mr. Balasubba Reddy Mamilla (DIN: 01998852), who retires by rotation at this meeting, be and is hereby reappointed as a Director of the Company, whose period of office shall be liable to retire by rotation.” SPECIAL BUSINESS: 3. TO APPOINT MR. AMIREDDY VENKATESU REDDY (DIN: 11087687) AS A DIRECTOR AND WHOLE- TIME DIRECTOR OF THE COMPANY: To consider and, if thought fit, to pass with or without modifications, the following resolution as a Special Resolution: “RESOLVED THAT pursuant to the provisions of Sections 152, 161 and any other applicable provisions of the Companies Act, 2013, provisions of SEBI (LODR) Regulations, 2015 and the rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force), Mr. Amireddy Venkatesu Reddy (DIN: 11087687), who was appointed by the Board of Directors as an Additional Director (Category: Executive Director) of the Company on recommendation of Nomination and Remuneration Committee with effect from 23rd May, 2026 who holds office up to the date of this Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier and who is eligible for appointment and has consented to act as Director of the Company, be and is hereby appointed as a Director of the Company, liable to retire by rotation.” “RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197, 203, and other applicable provisions, if any, of the Companies Act, 2013 (the "Act") read with Schedule V to the Act, and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and Regulation 17(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and based on the recommendations of the Nomination and Remuneration Committee and the Board of Directors, consent of the members be and is hereby accorded for the appointment of Mr. Amireddy Venkatesu Reddy (DIN: 11087687) as Whole Time Director of the Company for a term of Three (3) years w.e.f. 23rd May, 2026 at a rem [Showing first 8,000 characters — download PDF for full document]